Autism | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2018

Autism spectrum disorder (ASD) is a heterogeneous, neurodevelopmental disorder with core symptoms including deficits in social interaction, difficulties in communication, and restricted, repetitive behaviors. Behavioral and developmental therapies are the cornerstone of ASD treatment, regardless of severity, and many patients also receive drug therapy to help manage specific symptoms or comorbidities, such as attention deficit, hyperactivity, irritability, and aggression. The only FDA-approved treatments for ASD are risperidone and aripiprazole, which are indicated for irritability associated with ASD. Other drug classes that may be used in the treatment of ASD include antidepressants, stimulants, and antiepileptics. Significant unmet need remains for pharmacological therapies to treat the core symptoms of ASD, but it is unclear if any pipeline agent can capitalize on this significant commercial opportunity.


  •  How large is the diagnosed prevalent ASD population in the United States and EU5 and how will it change through 2027?
  • What is the current treatment landscape for ASD patients and how will it change in the next 10 years? What clinical needs remain unfulfilled?
  •  Which emerging therapies do ASD specialists consider the most promising and which are likely to launch by 2027? What is the commercial impact of these new ASD therapies?

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report